Akoya biosciences and singapore translational cancer consortium (stcc) partner on super study designed to advance cancer immunophenotyping for patients in singapore

The stcc unified pd1/pdl1 evaluation of response (super) study is a multi-institutional study led by stcc with the goal of identifying predictors of pd1 immunotherapy response in an asian real-world setting, bringing together singapore's public healthcare and research institutions in the translational cancer research ecosystem, comprising the national cancer centre singapore (nccs), national university cancer institute, singapore (ncis), national university hospital (nuh), national university of singapore (nus), singapore general hospital (sgh) and the agency for science, technology and research (a*star). the partnership between akoya biosciences and stcc will leverage akoya biosciences' phenocode™ discovery io60 panel in the super study to immunophenotype matched pairs of immuno-oncology exceptional responders and hyper-progressors through advanced spatial multiplexed analyses.
AKYA Ratings Summary
AKYA Quant Ranking